Evolution of the sentinel lymph node procedure following the approval of adjuvant anti-PD-1 therapy for stage IIB and IIC melanoma: A multicenter study from RICMEL database
Although prognostic scores or new marketing authorization could suggest performing fewer SLNBs, the reduced use of SLNB due to earlier access to immunotherapy may result in inaccurate melanoma staging, potentially affecting prognosis and treatment decisions.
Authors
- R. Levard
- A. Dompmartin
- J.-M. L’Orphelin
- T. Tagmouti
- J. Cassecuel
- G. Quereux
- M. Deriouich
- D. Sanogo
- B. Dreno
- A. Khammari
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Normandie Université (FR)
- Cancers et Préventions (FR)
- Nantes Université (FR)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- Annales de Dermatologie et de Vénéréologie
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1016/j.annder.2025.103463
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00